Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
List view / Grid view
Filter the results
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
In this article, Janssen Pharmaceuticals’ Global Head of Discovery Neuroscience discusses the findings of their recent study which highlighted new roles for two gene products involved in human deafness which could enable drug discovery for some prevalent auditory disorders.
Scientists developed a new culture technique for alveolospheres which they used to study how alveolar cells respond to SARS-CoV-2 infection.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
The new approach enables researchers to isolate brain cells associated with Parkinson's disease and study their gene expression patterns.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.